Literature DB >> 11893912

Therapeutic window for nicotinamide following transient focal cerebral ischemia.

Issam A Ayoub1, Kenneth I Maynard.   

Abstract

The therapeutic window with the neuroprotectant nicotinamide (NAm) was tested in a model of stroke. Either 2, 4 or 6 h after the onset of transient (2 h) focal cerebral ischemia, Wistar rats received either saline or NAm (500 mg/kg). Sensory and motor behavioral scores and weight of the animals were obtained before surgery, and 2 h, 3 and 7 days after stroke onset. Cerebral infarct volumes were measured on day 7 after sacrifice. NAm given 4 or 6 h after stroke onset significantly (p<0.05) reduced the cerebral infarction and improved the behavioral scores, respectively, compared to saline-injected animals. There was a non-significant improvement in weight gained by NAm-treated rats at 3 and 7 days following stroke compared to the saline-injected controls.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11893912     DOI： 10.1097/00001756-200202110-00008

Source DB:  PubMed          Journal:  Neuroreport        ISSN： 0959-4965            Impact factor:   1.837


  11 in total

Review 1.  Nicotinamide is an inhibitor of SIRT1 in vitro, but can be a stimulator in cells.

Authors:  Eun Seong Hwang; Seon Beom Song
Journal:  Cell Mol Life Sci       Date:  2017-04-17       Impact factor: 9.261

Review 2.  Mitochondrial dysfunction and NAD(+) metabolism alterations in the pathophysiology of acute brain injury.

Authors:  Katrina Owens; Ji H Park; Rosemary Schuh; Tibor Kristian
Journal:  Transl Stroke Res       Date:  2013-08-10       Impact factor: 6.829

Review 3.  The importance of NAD in multiple sclerosis.

Authors:  W Todd Penberthy; Ikuo Tsunoda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

4.  Nicotinamide reduces hypoxic ischemic brain injury in the newborn rat.

Authors:  Yangzheng Feng; Ian A Paul; Michael H LeBlanc
Journal:  Brain Res Bull       Date:  2005-12-15       Impact factor: 4.077

5.  Sustained delivery of nicotinamide limits cortical injury and improves functional recovery following traumatic brain injury.

Authors:  Andrea M Goffus; Gail D Anderson; Michael Hoane
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

Review 6.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 7.  NAD(+) Metabolism in Age-Related Hearing Loss.

Authors:  Hyung-Jin Kim; Gi-Su Oh; Seong-Kyu Choe; Tae Hwan Kwak; Raekil Park; Hong-Seob So
Journal:  Aging Dis       Date:  2014-04-01       Impact factor: 6.745

8.  Nicotinamide treatment induces behavioral recovery when administered up to 4 hours following cortical contusion injury in the rat.

Authors:  M R Hoane; J L Pierce; M A Holland; G D Anderson
Journal:  Neuroscience       Date:  2008-05-02       Impact factor: 3.590

9.  Variation in chronic nicotinamide treatment after traumatic brain injury can alter components of functional recovery independent of histological damage.

Authors:  Michael R Hoane; Jeremy L Pierce; Nicholas A Kaufman; Jason E Beare
Journal:  Oxid Med Cell Longev       Date:  2008 Oct-Dec       Impact factor: 6.543

Review 10.  New Therapeutic Concept of NAD Redox Balance for Cisplatin Nephrotoxicity.

Authors:  Gi-Su Oh; Hyung-Jin Kim; AiHua Shen; Su-Bin Lee; Sei-Hoon Yang; Hyeok Shim; Eun-Young Cho; Kang-Beom Kwon; Tae Hwan Kwak; Hong-Seob So
Journal:  Biomed Res Int       Date:  2016-01-05       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.